Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing

Christopher B. Benton, MD, Ahmed Al Rawi, Feng Wang, PhD, Jianhua Zhang, PhD, Jeffrey L. Jorgensen, MD PhD, Hong Mu, MD PhD, Wendy Schober, Zoe Alaniz, Curtis Gumbs, Andy Futreal, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Nicholas Navin, PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2018-99-120260

Published: 2018

Journal Articles

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Peter P. Ruvolo, PhD, Huaxian Ma, MS, Vivian Ruvolo, MS, Xiaorui Zhang, BS, Hong Mu, MD PhD, Tomoko Yasuhiro, Kohei Tanaka, Toshio Yoshizawa, PhD, Weiguo Zhang, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2018-99-112211

Published: 2018

Journal Articles

IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia

Hong Mu, MD PhD, Huaxian Ma, MS, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya P. Velasquez, MD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2724.

https://doi.org/10.1182/blood-2018-99-116811

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Xiangmeng Wang, Po Yee Mak, Wencai Ma, Xiaoping Su, PhD, Hong Mu, MD PhD, Wenjing Tao, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2018) 132 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2018-99-118367

Published: 2018

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL

Sujan Piya, PhD, Hong Mu, MD PhD, Seemana Bhattacharya, PhD, Teresa McQueen, MS, Richard E Davis, BSPharm, MS, Vivian Ruvolo, PhD, Natalia Baran, PhD MD, Yimin Qian, PhD, Kanak Raina, PhD, Craig M Crews, PhD, M. James You, MD PhD, Patrick Zweider McKay, MDPhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 716.

https://doi.org/10.1182/blood.V130.Suppl_1.716.716

Published: 2017

Journal Articles

Comparison of Induction Chemotherapy in NSG and NOD- Rag1 null IL2rg null Mouse Models of FLT3 Mutant AML

Hong Mu, MD PhD, Marina Konopleva, MD PhD, Rodrigo Jacamo, PhD, Bing Z Carter, PhD, Teresa McQueen, MS, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2692.

https://doi.org/10.1182/blood.V130.Suppl_1.2692.2692

Published: 2017

Journal Articles

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

Xiangmeng Wang, PhD, Po Yee Mak, Hong Mu, MD PhD, Wenjing Tao, PhD, Jonathan A Pachter, PhD, David T Weaver, PhD, Bing Xu, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2017) 130 (Supplement 1): 2653.

https://doi.org/10.1182/blood.V130.Suppl_1.2653.2653

Published: 2017

Journal Articles

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Vivian Ruvolo, PhD, Neel Madhukar, Ran Zhao, Hong Mu, MD PhD, Lauren Heese, Kensuke Kojima, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Neil Charter, Sean Deacon, Olivier Elemento, PhD, Joshua E. Allen, PhD, Wolfgang Oster, MD, Martin Stogniew, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2616.

https://doi.org/10.1182/blood.V130.Suppl_1.2616.2616

Published: 2017

Journal Articles

Novel ARC//IL1β/PGE2/β-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML

Bing Z Carter, PhD, Po Yee Mak, Xiangmeng Wang, PhD, Hong Mu, MD PhD, Wenjing Tao, PhD, Vivian Ruvolo, PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 3776.

https://doi.org/10.1182/blood.V130.Suppl_1.3776.3776

Published: 2017

Journal Articles

Bone Marrow Stromal Cells Induce ALDH+ Stem Cell Phenotype and Chemotherapy Resistance in AML Cells through TGF-β1 Mediated Signaling: Reversal By TGFβ Inhibitor Galunisertib

Ximin Zhou, Bin Yuan, Yuanqing Yan, Khoa Nguyen, Vivian Ruvolo, PhD, Hong Mu, MD PhD, Teresa McQueen, MS, Elizabeth J Shpall, MD, Kim-Ann Do, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Venkata Lokesh Battula, PhD

Blood (2017) 130 (Supplement 1): 1163.

https://doi.org/10.1182/blood.V130.Suppl_1.1163.1163

Published: 2017

Journal Articles

Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML

Bing Z Carter, PhD, Po Yee Mak, Hong Mu, MD PhD, Duncan Mak, Ej Dettman, Michael Cardone, Xiangmeng Wang, PhD, Wendy Schober, Wenjing Tao, PhD, Takahiko Seki, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 4170.

https://doi.org/10.1182/blood.V130.Suppl_1.4170.4170

Published: 2017

Journal Articles

The Pan-FLT3/BTK Multi-Kinase Inhibitor CG '806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

Charlie Ly, BS, Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hong Mu, MD PhD, Hongying Zhang, MD, William Rice, PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 3348.

https://doi.org/10.1182/blood.V130.Suppl_1.3348.3348

Published: 2017

Journal Articles

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Xiangmeng Wang, Po Yee Mak, MPhil, Hong Mu, MD PhD, Xuejie Jiang, Duncan Mak, BSc, MPhil, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Bing Xu, PhD, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2016) 128 (22): 1574.

https://doi.org/10.1182/blood.V128.22.1574.1574

Published: 2016

Journal Articles

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Qi Zhang, MD PhD, Lina Han, MD PhD, Ce Shi, MD PhD, Rongqing Pan, MS, Man Chun John MA, PhD, Jeremy Ryan, PhD, Stephen E Kurtz, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Helen Ma, MS, Michael Andreeff, MD PhD, Yingchang Mi, MD PhD, Jeffrey W. Tyner, PhD, Joel Leverson, Anthony Letai, MD PhD, Richard Eric Davis, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 101.

https://doi.org/10.1182/blood.V128.22.101.101

Published: 2016

Journal Articles

Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model

Weiguo Zhang, MD, PhD, Charlie Ly, Qi Zhang, MDPhD, Hong Mu, MD PhD, Venkata Lokesh Battula, PhD, Nalini Patel, Wendy Schober, Xin Han, MD MS, William E. Fogler, PhD, John L Magnani, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3519.

https://doi.org/10.1182/blood.V128.22.3519.3519

Published: 2016

Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Philip L Lorenzi, PhD, Teresa McQueen, MS, Eric Richard Davis, MD, Vivian Ruvolo, MS, Natalia Baran, PhD, Yimin Qian, PhD, Craig Crews, PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2016) 128 (22): 748.

https://doi.org/10.1182/blood.V128.22.748.748

Published: 2016

Journal Articles

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

Peter Ruvolo, PhD, Huaxian Ma, BS, Vivian Ruvolo, MS, Hong Mu, MD PhD, Wendy Schober, Tomoko Yasuhiro, Toshio Yoshizawa, PhD, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Joseph D Khoury, MD, Jorge Cortes, MD, Michael Andreeff, MD PhD, Sean M. Post, PhD

Blood (2016) 128 (22): 3939.

https://doi.org/10.1182/blood.V128.22.3939.3939

Published: 2016

Journal Articles

Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo

Xuejie Jiang, Po Yee Mak, MPhil, Hong Mu, MD PhD, Duncan Mak, BSc, MPhil, Qi Zhang, MD PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2016) 128 (22): 2828.

https://doi.org/10.1182/blood.V128.22.2828.2828

Published: 2016

NARROW

Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL

Comparison of Induction Chemotherapy in NSG and NOD- Rag1 null IL2rg null Mouse Models of FLT3 Mutant AML

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Novel ARC//IL1β/PGE2/β-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML

Bone Marrow Stromal Cells Induce ALDH+ Stem Cell Phenotype and Chemotherapy Resistance in AML Cells through TGF-β1 Mediated Signaling: Reversal By TGFβ Inhibitor Galunisertib

Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML

The Pan-FLT3/BTK Multi-Kinase Inhibitor CG '806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only